Enzon's PEG-L-asparaginase
Executive Summary
Clinical trial comparing the firm's investigational agent to L-asparaginase marketed by Merck (Elspar) and an investigational version produced by the National Cancer Institute (Erwinase) in acute lymphocytic leukemia began Nov. 17 at six centers in U.S. Trial, partially supported by NCI, includes 150 children with newly diagnosed acute lymphocytic leukemia. Study centers include the Dana-Farber Cancer Institute in Boston, University of Puerto Rico, Maine Medical Center, University of Rochester, Ochsner Clinic in New Orleans, and the University of Massachusetts.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.